Keros Therapeutics, Inc. (KROS) has been a topic of discussion on Reddit following a downgrade by Guggenheim. The downgrade has sparked conversations among investors, with some expressing concern over the potential implications for the company's future performance. The lack of specific news detailing the reasons behind the downgrade has left room for speculation among the community.
On Reddit, users are actively discussing the downgrade, with some questioning the timing and rationale behind Guggenheim's decision. One user commented, "Keros getting downgraded by Guggenheim is a surprise. I wonder what they see that we don't." Another user speculated, "Could this be related to their recent trial results? Or maybe it's just a market overreaction." The discussions reflect a mix of skepticism and curiosity, as investors try to piece together the potential impact on Keros's stock.
As of 12:29 PM on December 16, 2024, Keros Therapeutics (KROS) is trading at $19.045, reflecting a slight increase of 1.14% from the previous close.